药学学报, 2021, 56(4): 966-971
引用本文:
江爽, 韩燕星, 蒋建东, 王玉红*. 葛根素抗动脉粥样硬化作用及其机制的研究进展[J]. 药学学报, 2021, 56(4): 966-971.
JIANG Shuang, HAN Yan-xing, JIANG Jian-dong, WANG Yu-hong*. The anti-atherosclerotic effect and mechanism of puerarin[J]. Acta Pharmaceutica Sinica, 2021, 56(4): 966-971.

葛根素抗动脉粥样硬化作用及其机制的研究进展
江爽, 韩燕星, 蒋建东, 王玉红*
中国医学科学院、北京协和医学院药物研究所, 北京 100050
摘要:
近年来,随着人们生活水平的提高和工作节奏的加快,心脑血管病的发病率和病死率都呈明显的上升趋势。动脉粥样硬化(atherosclerosis,AS)是心脑血管病的主要病理基础,引起动脉粥样硬化的危险因素很多。葛根素的药理作用研究较多,大量临床资料证实,葛根素对动脉粥样硬化所致心血管疾病有确切疗效。近年来,对葛根素研究的热点主要集中于抗动脉粥样硬化相关的作用及其机制方面,本文就此方面的研究进展作一综述。
关键词:    葛根素      心血管疾病      动脉粥样硬化      作用机制     
The anti-atherosclerotic effect and mechanism of puerarin
JIANG Shuang, HAN Yan-xing, JIANG Jian-dong, WANG Yu-hong*
Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Abstract:
In recent years, with the improvement in living standards, the morbidity and mortality of cardiovascular and cerebrovascular diseases has increased markedly. Atherosclerosis is the main pathological basis for cardiovascular and cerebrovascular diseases, and there are many risk factors for atherosclerosis. The pharmacological effects of puerarin are broad, and considerable clinical data confirms that puerarin has a definite effect on cardiovascular diseases resulting from atherosclerosis. The use of puerarin for atherosclerosis has increased in recent years. This article reviews the effect and mechanism of puerarin on atherosclerosis.
Key words:    puerarin    cardiovascular disease    atherosclerosis    mechanism   
收稿日期: 2020-11-27
DOI: 10.16438/j.0513-4870.2020-1833
基金项目: 国家自然科学基金资助项目(81703583);十三五重大新药创制子课题(2018ZX09711001-004).
通讯作者: 王玉红,Tel:86-10-63017906,E-mail:wangyh@imm.ac.cn
Email: wangyh@imm.ac.cn
相关功能
PDF(676KB) Free
打印本文
0
作者相关文章
江爽  在本刊中的所有文章
韩燕星  在本刊中的所有文章
蒋建东  在本刊中的所有文章
王玉红*  在本刊中的所有文章

参考文献:
[1] Xie SQ, Cheng WJ, Zhu J, et al. Research progresson on the mechanism of atherosclerosis[J]. World J Complex Med (世界复合医学), 2016, 2:85-90.
[2] Wei AZ, Yang JF. A brief discussion on the research progress of atherosclerosis[J]. J Clin Med Liter (临床医药文献电子杂志), 2014, 1:1866-1867, 1869.
[3] Ma YF, Liu XW, Wen TT, et al. Protective effect of P13K/Akt signaling pathway in puerarin pretreatment against myocardial ischemia-reperfusion injury in rat[J]. J Chongqing Med Univ (重庆医科大学学报), 2009, 34:1673-1676.
[4] Zu DL, Zhu GY, Jiang YM, et al. To compare the curative effect of the antiplatelet therapy between puerarin injection and Xueshuantong injection among patients with unstable angina after percutaneous coronary stent implantation[J]. Chin Arch Tradit Chin Med (中华中医药学刊), 2011, 29:2012-2014.
[5] Wei SY. Progress on cardiovascular protections and mechanism research of puerarin[J]. China J Chin Mater Med (中国中药杂志), 2015, 40:2278-2284.
[6] Bao LD, Zhang Y, Wei GM, et al. The anti-atherosclerotic effects of puerarin on induced-atherosclerosis in rabbits[J]. Biomed Pap Med Fac Univ Palacký Olomouc Czech Rupub, 2015, 159:53-59.
[7] Zhang J. Clinical effect of atorvastatin calcium combined with clopidogrel in the treatment of carotid atherosclerosis in patients with acute cerebral infarction[J]. PSY (心理月刊), 2020, 15:227.
[8] Xue JE. Clinical observation of puerarin injection combined with atorvastatin calcium in the treatment of carotid atherosclerotic plaque[J]. China's Naturopathy (中国民间疗法), 2020, 28:96-98.
[9] Liu XY, Dong PS, Wang YY, et al. Clinical study on puerarin injection combined with atorvastatin calcium in treatment of carotid atherosclerotic plaque[J]. Drugs Clin (现代药物与临床), 2018, 33:796-800.
[10] Yang HX. Clinical analysis of coronary atherosclerotic heart disease[J]. Prev Treat Cardiovas Dis (心血管病防治知识), 2014, 5:33-35.
[11] He GX, Ma YH, Liu HY, et al. Clinical study of puerarin combined with α-lipoic acid in the treatment of diabetes mellitus with carotid atherosclerosis[J]. China Med Herald (中国医药导报), 2020, 17:82-85.
[12] Yan LP, Chan SW, Chan ASC, et al. Puerarin decreases serum total cholesterol and enhances thoracic aorta endothelial nitric oxide synthase expression in diet-induced hypercholesterolemic rats[J]. Life Sci, 2006, 79:324-330.
[13] Hu ZP, Wang BN. Advances in research of vascular endothelial dysfunction and hypertension[J]. Med Recapit (医学综述), 2007, 13:255-257.
[14] Shi RL, Zhang JJ. Protective effect of puerarin on vascular endothelial cell apoptosis induced by chemical hypoxia in vitro[J]. Acta Pharm Sin (药学学报), 2003, 38:103-107.
[15] Guan HM, Zhang XM, Li YQ, et al. Protective effects of hydroxyethylpuerain on cultured bovine cerebral microvascular endothelial cells damaged by hydrogen peroxide[J]. Acta Pharm Sin (药学学报), 2005, 40:220-224.
[16] Kim HG, Hwang YP, Hien TT, et al. Puerarin activates endothelial nitric oxide synthase through estrogen receptor-dependent PI3-kinase and calcium-dependent AMP-activated protein kinase[J]. Toxicolo Appl Pharmacol, 2011, 257:48-58.
[17] Cheng M, Li X, Guo ZL, et al. Puerarin accelerates re-endothelialization in a carotid arterial injury model:impact on vasodilator concentration and vascular cell functions[J]. J Cardiovas Pharmacol, 2013, 62:361-368.
[18] Mao HM, Si DZ, Liu XH. Research progress in the mechanism of platelet-derived growth factor on vascular smooth muscle cells[J]. Prog Physiol Sci (生理科学进展), 2015, 5:359-364.
[19] Liu S, Wang LY, Wang W, et al. Puerarin in preventing restenosis after rabbit iliac artery balloon injury[J]. Chin J Arterioscler (中国动脉硬化杂志), 2004, 12:159-161.
[20] Wan Q, Liu ZY, Yang YP. Puerarin inhibits vascular smooth muscle cells proliferation induced by fine particulate matter via suppressing of the p38 MAPK signaling pathway[J]. BMC Complement Altern Med, 2018, 18:146.
[21] Jing T, Wang LY, Wang W, et al. Study on expression of vascular smooth muscle cell apoptosis gene in atherosclerosis tissue induced by puerarin[J]. Chin Pharm J (中国药学杂志), 2003, 38:667-670.
[22] Wei Y, Shen XJ. Experimental study of icariin and puerarin on inducing apoptosis of vascular smooth muscle cells[J]. Tradit Chin Med Res (中医研究), 2009, 22:17-18.
[23] Pan HM. Study on the mechanism of puerarin on atherosclerotic rabbits[J]. Global Tradit Chin Med (环球中医药), 2015, 8:56-57.
[24] Deng Y, Lei TW, Li HM, et al. ERK5/KLF2 activation is involved in the reducing effects of puerarin on monocyte adhesion to endothelial cells and atherosclerotic lesion in apolipoprotein E-deficient mice[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864:2590-2599.
[25] Zhang CM, Wang GP. Effect of puerarin on oxLDL-induced TLR4-NF-κB signal transduction pathway in THP-1 macrophages[J]. Chin J Immunol (中国免疫学杂志), 2019, 35:2705-2710.
[26] Yang LL. Oxidized low-density lipoprotein and atherosclerosis[J]. Foreign Med Sci (Intern Med) (国外医学:内科学分册), 2000, 27:58-60.
[27] Zhang H, Zhai ZH, Zhou HY, et al. Puerarin inhibits oxLDL-induced macrophage activation and foam cell formation in human THP1 macrophage[J]. Biomed Res Int, 2015, 2015:403616.
[28] Li CH, Gong D, Chen LY, et al. Puerarin promotes ABCA1-mediated cholesterol efflux and decreases cellular lipid accumulation in THP-1 macrophages[J]. Eur J Pharmacol, 2017, 811:74-86.
[29] Feng X, Li SW, Li HX, et al. Comparison of the anticoagulant, anti-platelet effects of puerarin injection and low molecular weight heparin sodium injection in vitro using Sonoclot[J]. Chin J Evid Base Cardiovas Med (中国循证心血管医学杂志), 2017, 9:183-186.
[30] Yu C, Fan HY. Effects of puerarin on blood coagulation[J]. Chin J Hosp Pharm (中国医院药学杂志), 2011, 31:1777-1779.
[31] Deng HF, Wang XL, Sun H, et al. Puerarin inhibits expression of tissue factor induced by oxidative low-density lipoprotein through activating the PI3K/Akt/eNOS pathway and inhibiting activation of ERK1/2 and NF-κB[J]. Life Sci, 2017, 191:115-121.
[32] He XY, Wang JY, Song N, et al. Potential molecular mechanisms of puerarin in treatment of atherosclerosis based on network pharmacology[J]. Chin Arch Tradit Chin Med (中华中医药学刊), 2020, 38:116-120, 262-263.
相关文献:
1.高凤凤, 裴艳玲, 任越, 陈紫军, 卢建秋, 张燕玲.基于网络药理学与分子对接技术研究黄精抗动脉粥样硬化的作用机制[J]. 药学学报, 2020,55(11): 2642-2650